Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

키워드

참고문헌 (63)

1. Lavanchy D, "Evolving epidemiology of hepatitis C virus", Clin Microbiol Infect, 17, pp.107~115 (2011)
2. Singal AG, "A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus", Clin Gastroenterol Hepatol, 8, pp.280~288 (2010)[DOI]
3. Morgan RL, "Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies", Ann Intern Med, 158(5), pp.329~337 (2013)
4. Huang CF, "Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication", J Hepatol, 61, pp.67~74 (2014)
5. Yu ML, "A sustained virological response to interferon or interferon", ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C : a nationwide, multicentre study in Taiwan, 2006, pp.11, 985~994
6. Gane E, "Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment", N Engl J Med, 377, pp.1448~1455 (2017)
7. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
8. Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", N Engl J Med, 370, pp.1889~1898 (2014)
9. Forns X, "Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis(EXPEDITION-1) : a single-arm, open-label, multicentre phase 3 trial", Lancet Infect Dis, 17, pp.1062~1068 (2017)
10. Zeuzem S, "Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3infection", N Engl J Med, 378, pp.354~369 (2018)
11. Yoshida H, "Inhibition of Hepatocarcinogenesis by Interferon Therapy", Ann Intern Med, 131, pp.174~181 (1999)
12. El-Serag HB, "Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection", Hepatology, 64, pp.130~137 (2016)
13. Janjua NZ, "Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada", J Hepatol, 66, pp.504~513 (2017)
14. van der Meer AJ, "Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis", JAMA, 308, pp.2584~2593 (2012)
15. van der Meer AJ, "Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication", J Hepatol, 66, pp.485~493 (2017)
16. Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis : a retrospective study", Hepatology, 45, pp.579~587 (2007)
17. Shiratori Y, "Antiviral therapy for cirrhotic hepatitis C : association with reduced hepatocellular carcinoma development and improved survival", Ann Intern Med, 142, pp.105~114 (2005)
18. Aleman S, "A risk for hepatocellular carcinoma persists longterm after sustained virologic response in patients with hepatitis Cassociated liver cirrhosis", Clin Infect Dis, 57, pp.230~236 (2013)
19. Nahon P, "Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications", Gastroenterology, 152, pp.142~156 (2017)[DOI]
20. Conti F, "Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals", J Hepatol, 65, pp.727~733 (2016)
21. Reig M, "Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy", J Hepatol, 65, pp.719~726 (2016)
22. Ravi S, "Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis", Gastroenterology, 152, pp.911~912 (2017)
23. Li DK, "The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals : an ERCHIVES study", Hepatology, 67, pp.2244~2253 (2018)
24. Ioannou GN, "HCV eradication induced by directacting antiviral agents reduces the risk of hepatocellular carcinoma", J Hepatol, 68, pp.25~32 (2018)
25. Nagaoki Y, "The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy", PLoS One, 12, pp.e0182710~ (2017)
26. Waziry R, "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review, meta-analyses, and meta-regression", J Hepatol, 67, pp.1204~1212 (2017)
27. Mettke F, "Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis", Aliment Pharmacol Ther, 47, pp.516~525 (2018)
28. Kanwal F, "Risk of hepatocellular cancer in HCV patients treated with directacting antiviral agents", Gastroenterology, 153, pp.996~1005 (2017)[DOI]
29. Yamashita N, "Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon : significance of lifelong periodic cancer screening for improving outcomes", J Gastroenterol, 49, pp.1504~1513 (2014)
30. Yoshida H, "Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C", Gut, 53, pp.425~430 (2004)
31. Ikeda M, "Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon", J Gastroenterol, 40, pp.148~156 (2005)
32. Nagaoki Y, "Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy : a large-scale, long-term cohort study", J Gastroenterol Hepatol, 31, pp.1009~1015 (2016)
33. European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
34. AASLD, "IDSA HCV Guidance Panel", Hepatitis C guidance : AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, 2015, pp.62, 932~954
35. Jacobson IM, "Safety and efficacy of elbasvir", grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis : an integrated analysis, 2017, pp.152, 1372~1382
36. European Association for the Study of the Liver, "EASL-ALEH Clinical Practice Guidelines : non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
37. Masuzaki R, "Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography", Hepatology, 49, pp.1954~1961 (2009)
38. Lin ZH, "Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis : an updated meta-analysis", Hepatology, 53, pp.726~736 (2011)
39. Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
40. Sandrin L, "Transient elastography : a new noninvasive method for assessment of hepatic fibrosis", Ultrasound Med Biol, 29, pp.1705~1713 (2003)
41. Holmberg SD, "Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort", Clin Infect Dis, 57, pp.240~246 (2013)
42. Vallet-Pichard A, "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
43. Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
44. Castéra L, "Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C", Gastroenterology, 128, pp.343~350 (2005)
45. Afdhal NH, "Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C : a United States multicenter study", Clin Gastroenterol Hepatol, 13, pp.772~779 (2015)[DOI]
46. Toyoda H, "Risk factors of hepatocellular carcinoma development in noncirrhotic patients with sustained virologic response for chronic hepatitis C virus infection", J Gastroenterol Hepatol, 30, pp.1183~1189 (2015)
47. Akuta N, "Liver fibrosis and body mass index predict hepatocarcinogenesis following eradication of hepatitis C virus RNA by direct-acting antivirals", Oncology, 91, pp.341~347 (2016)
48. Kobayashi M, "Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection", J Med Virol, 89, pp.476~483 (2017)
49. Keol Lee, "Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index", Gut and Liver, 10(5), pp.796~802 (2016), 거트앤리버 소화기연관학회협의회
50. Yu ML, "A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy", Hepatology, 44, pp.1086~1097 (2006)
51. Jung KS, "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)", Hepatology, 53, pp.885~894 (2011)
52. Masuzaki R, "Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography", J Clin Gastroenterol, 42, pp.839~843 (2008)
53. Wang JH, "Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy", Liver Int, 36, pp.1793~1799 (2016)
54. Hye Won Lee, "Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response", Gut and Liver, 10(3), pp.429~436 (2016), 거트앤리버 소화기연관학회협의회
55. Tachi Y, "Predictive ability of laboratory indices for liver fibrosis in patients with chronic hepatitis C after the eradication of hepatitis C virus", PLoS One, 10, pp.e0133515~ (2015)
56. D’Ambrosio R, "Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon", PLoS One, 11, pp.e0155967~ (2016)
57. Sherman M, "Surveillance for hepatocellular carcinoma", Best Pract Res Clin Gastroenterol, 28, pp.783~793 (2014)
58. Sarasin FP, "Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis", Am J Med, 101, pp.422~434 (1996)
59. Nouso K, "Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances", J Gastroenterol Hepatol, 23, pp.437~444 (2008)
60. Lin OS, "Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C", Aliment Pharmacol Ther, 19, pp.1159~1172 (2004)
61. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
62. Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
63. Omata M, "APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing", Hepatol Int, 10, pp.681~701 (2016)

관련 논문AI추천